Exagamglogene autotemcel (Casgevy)

Gene therapy / editing

Also known as CTX001

Approvedregulatory verdict

Evidence outlook

Approved: Sickle Cell Disease, Transfusion-Dependent Beta Thalassemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Also approved (2)
EU
  • Severe sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta thalassemia, 12 years and older (conditional marketing authorisation)
Product first approved 2024finance.yahoo.com
UK
  • Sickle cell disease and transfusion-dependent beta thalassemia, 12 years and older
Product first approved 2023MHRA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Sickle Cell Disease
NCT05951205 · Vertex Pharmaceuticals Incorporated
2027-07-31 – 2033-12-31 · Sickle Cell Disease
What this study did
Other / comorbidity
NCT05356195 · Vertex Pharmaceuticals Incorporated
2022-05-03 – 2027-11-14 · Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
What this study did
Phase 2/3 (2)
Sickle Cell Disease
Other / comorbidity
Phase 1/2 (1)
Other / comorbidity
NCT07392255 · Complement Therapeutics
2025-12-30 – 2032-06-30 · Geographic Atrophy Secondary to Age-related Macular Degeneration
What this study did
Phase 1 (2)
Other / comorbidity
NCT07901933 · Cajal Therapeutics Inc.
2026-11 – 2027-11 · Chronic Kidney Disease, Anemia
What this study did
NCT07577817 · Cajal Therapeutics Inc.
2026-06 – 2026-12-30 · Anemia, Iron Deficiencies, Chronic Kidney Disease
What this study did

Competitive landscape

This drug's own stage for Sickle Cell Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Exagamglogene Autotemcel (Casgevy): this drugApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)Weak signalNo reviewed efficacy summary in this indication
Crizanlizumab-Tmca (Adakveo)ApprovedMonoclonal antibodyP-selectinPartial signalFeatured results are non-efficacy only in this race
Hydroxyurea (Droxia)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Siklos)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Xromi)ApprovedSmall moleculeRibonucleotide reductaseWeak signalNo reviewed efficacy summary in this indication
L-Glutamine (Endari)ApprovedSmall moleculeAmino AcidReliable signal
NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15)
Lovotibeglogene Autotemcel (Lyfgenia)ApprovedGene therapy / editingBeta-globin gene addition (betaA-T87Q)not yet gradedNo reviewed efficacy summary in this indication
EtavopivatPhase 3—Pyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Mitapivat (Pyrukynd)Phase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Decitabine / Tetrahydrouridine (NDec)Phase 2Small moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
ITU512Phase 1/2Small moleculeWIZ transcription factornot yet gradedNo reviewed efficacy summary in this indication
Nula-CelPhase 1/2Gene or cell therapy (subtype unspecified)HBB gene (sickle mutation correction)not yet gradedNo reviewed efficacy summary in this indication
Ristoglogene AutogetemcelPhase 1/2Gene therapy / editingHBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 1Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
SCD-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
VAS-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)Reliable signal
NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Exagamglogene autotemcel (Casgevy) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
June 2027 (2)
Phase 3Sickle Cell DiseaseActive not recruiting
Est. primary completion 2027-06-06 · NCT05329649 · CT.gov ↗
What to watch
Phase 3Sickle Cell DiseaseRecruiting
Est. primary completion 2027-06-09 · NCT05477563 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1Chronic Kidney Disease, AnemiaNot yet recruiting
Est. primary completion 2027-10 · NCT07901933 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, HemoglobinopathiesActive not recruiting
Est. primary completion 2027-11-14 · NCT05356195 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 1/2Geographic Atrophy Secondary to Age-related Macular DegenerationRecruiting
Est. primary completion 2028-05-31 · NCT07392255 · CT.gov ↗
What to watch
2039 (1)
September 2039 (1)
Phase 3Sickle Cell DiseaseEnrolling by invitation
Est. primary completion 2039-09-30 · NCT04208529 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 July 2026ApprovalFDA approves expanded use of CASGEVY for ages 2 and older
US, FDA · Source ↗
11 June 2026Filing submittedUK submission to expand CASGEVY use to younger children
UK, MHRA · Source ↗